Mi-Suk Kang Dufour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mi-Suk Kang Dufour has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Fatima Kakkar
Division of Infectious Diseases, CHU Sainte-Justine, Montréal, Canada
2 shared publications - Ari Bitnun
Division of Infectious Diseases, Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, ON M5G 1X8, Canada
1 shared publication Ariane Collaborators Alimenti
Centre d’infectiologie mère-enfant (CIME), Centre de recherche Azrieli du CHU Sainte-Justine, Montreal, Quebec, Canada
1 shared publicationBen Ben Tan
Centre d’infectiologie mère-enfant (CIME), Centre de recherche Azrieli du CHU Sainte-Justine, Montreal, Quebec, Canada
1 shared publication- Christian Renaud
Département de Microbiologie et Immunologie, Faculté de Médecine, Université de Montréal, Montreal, QC H3T 1C5, Canada
1 shared publication - Christian Renaud
Départment of Microbiology, Infectiology & Immunology
1 shared publication
Latest Publications
- Open Access
- 7 April 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (8) , 764-771
Clinical and Immunologic Impact of CMV Coinfection Among Children Living With HIV in Canada
Background: Although cytomegalovirus (CMV) disease has been well described among severely immunocompromised children living with HIV (CLWH), the impact of CMV coinfection, is not well understood. The objective of this study was to characterize the clinical and immunologic effects of CMV coinfection in CLWH in Canada. Methods: This is a substudy of the Early Pediatric Initiation, Canada Child Cure Cohort study, which enrolled CLWH in Canada between 2014 and 2018. CMV serostatus was determined at the first (baseline) study visit, and HIV-1 viral load (VL), CMV VL, and lymphocyte subsets were quantified every 3–6 months. For a subset of participants, CD4+ and CD8+ T cell subsets were analyzed using flow cytometry. The clinical outcomes were recorded retrospectively at the baseline visit and prospectively during the study period. Results: Of the 225 participants, 85.3% were CMV seropositive (CMV+) and 81% had suppressed HIV VL. While there were no significant differences in clinical outcomes between CMV+ and CMV− children, CMV+ children had lower frequencies of CD4+ T cells, higher frequencies of CD8+ T cells, and lower CD4/CD8 ratio at baseline than CMV− children. Children with CMV+ children also demonstrated a higher frequency of CD4+ effector memory cells, lower CD8+ naïve T cells, and higher frequencies of CD8+ terminally differentiated effector memory cells. These differences remained significant even after adjusting for HIV viral control. Conclusions: CMV coinfection is common among CLWH and is associated with distinct immunological changes despite the effective control of HIV replication with antiretroviral therapy. The long-term implications of these immunologic perturbations require further investigation.
- 7 April 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (8) , 764-771
Open AccessClinical and Immunologic Impact of CMV Coinfection Among Children Living With HIV in Canada
Background: Although cytomegalovirus (CMV) disease has been well described among severely immunocompromised children living with HIV (CLWH), the impact of CMV coinfection, is not well understood. The objective of this study was to characterize the clinical and immunologic effects of CMV coinfection in CLWH in Canada. Methods: This is a substudy of the Early Pediatric Initiation, Canada Child Cure Cohort study, which enrolled CLWH in Canada between 2014 and 2018. CMV serostatus was determined at the first (baseline) study visit, and HIV-1 viral load (VL), CMV VL, and lymphocyte subsets were quantified every 3–6 months. For a subset of participants, CD4+ and CD8+ T cell subsets were analyzed using flow cytometry. The clinical outcomes were recorded retrospectively at the baseline visit and prospectively during the study period. Results: Of the 225 participants, 85.3% were CMV seropositive (CMV+) and 81% had suppressed HIV VL. While there were no significant differences in clinical outcomes between CMV+ and CMV− children, CMV+ children had lower frequencies of CD4+ T cells, higher frequencies of CD8+ T cells, and lower CD4/CD8 ratio at baseline than CMV− children. Children with CMV+ children also demonstrated a higher frequency of CD4+ effector memory cells, lower CD8+ naïve T cells, and higher frequencies of CD8+ terminally differentiated effector memory cells. These differences remained significant even after adjusting for HIV viral control. Conclusions: CMV coinfection is common among CLWH and is associated with distinct immunological changes despite the effective control of HIV replication with antiretroviral therapy. The long-term implications of these immunologic perturbations require further investigation.
- Open Access
The Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection
While children have experienced less severe coronavirus disease (COVID-19) after SARS-CoV-2 infection than adults, the cause of this remains unclear. The objective of this study was to describe the humoral immune response to COVID-19 in child vs. adult household contacts, and to identify predictors of the response over time. In this prospective cohort study, children with a positive SARS-CoV-2 polymerase chain reaction (PCR) test (index case) were recruited along with their adult household contacts. Serum IgG antibodies against SARS-CoV-2 S1/S2 spike proteins were compared between children and adults at 6 and 12 months after infection. A total of 91 participants (37 adults and 54 children) from 36 families were enrolled. Overall, 78 (85.7%) participants were seropositive for anti-S1/S2 IgG antibody at 6 months following infection; this was higher in children than in adults (92.6% vs. 75.7%) (p = 0.05). Significant predictors of a lack of SARS-CoV-2 seropositivity were age ≥ 25 vs. < 12 years (odds ratio [OR] = 0.23, p = 0.04), presence of comorbidities (vs. none, adjusted OR = 0.23, p = 0.03), and immunosuppression (vs. immunocompetent, adjusted OR = 0.17, p = 0.02).
Open AccessThe Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection
While children have experienced less severe coronavirus disease (COVID-19) after SARS-CoV-2 infection than adults, the cause of this remains unclear. The objective of this study was to describe the humoral immune response to COVID-19 in child vs. adult household contacts, and to identify predictors of the response over time. In this prospective cohort study, children with a positive SARS-CoV-2 polymerase chain reaction (PCR) test (index case) were recruited along with their adult household contacts. Serum IgG antibodies against SARS-CoV-2 S1/S2 spike proteins were compared between children and adults at 6 and 12 months after infection. A total of 91 participants (37 adults and 54 children) from 36 families were enrolled. Overall, 78 (85.7%) participants were seropositive for anti-S1/S2 IgG antibody at 6 months following infection; this was higher in children than in adults (92.6% vs. 75.7%) (p = 0.05). Significant predictors of a lack of SARS-CoV-2 seropositivity were age ≥ 25 vs. < 12 years (odds ratio [OR] = 0.23, p = 0.04), presence of comorbidities (vs. none, adjusted OR = 0.23, p = 0.03), and immunosuppression (vs. immunocompetent, adjusted OR = 0.17, p = 0.02).